LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

LLY

761.21

-0.27%↓

JNJ

174.07

-1.65%↓

ABBV

221.11

+0.52%↑

UNH

335.52

-1.53%↓

AZN

76.8

-0.93%↓

Home・Lista de Ações・Cogent Biosciences Inc

Cogent Biosciences Inc

Abrir

12.57 -0.16

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.28

Máximo

12.74

Indicadores-chave
By Trading Economics
Rendimento	-1.5M -74M
Margem de lucro	-1,582.642
Funcionários	205
EBITDA	1.7M -72M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+66.83% upside

Dividendos
By Dow Jones
Próximos Ganhos	10 de nov. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	89M 1.8B
Abertura anterior	12.73
Fecho anterior	12.57

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

4.88 / 5.87 Suporte e Resistência

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de set. de 2025, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 de set. de 2025, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 de set. de 2025, 21:59 UTC

Ganhos

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 de set. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 de set. de 2025, 23:39 UTC

Conversa de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 de set. de 2025, 22:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 de set. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 de set. de 2025, 22:18 UTC

Aquisições, Fusões, Aquisições de Empresas

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 de set. de 2025, 21:00 UTC

Ganhos

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

17 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 19:59 UTC

Conversa de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 de set. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 de set. de 2025, 18:43 UTC

Conversa de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 de set. de 2025, 18:38 UTC

Conversa de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 de set. de 2025, 18:20 UTC

Conversa de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 18:18 UTC

Conversa de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 de set. de 2025, 18:14 UTC

Conversa de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 de set. de 2025, 17:59 UTC

Conversa de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 de set. de 2025, 17:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 de set. de 2025, 17:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 de set. de 2025, 16:51 UTC

Ganhos

Correct: Exor 1H Net Loss -EUR624M

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de set. de 2025, 16:34 UTC

Conversa de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 de set. de 2025, 16:25 UTC

Ganhos

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 de set. de 2025, 16:23 UTC

Ganhos

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

66.83% parte superior

Previsão para 12 meses

Média 20.92 USD 66.83%

Máximo 30 USD

Mínimo 10 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

4.88 / 5.87Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.